Reneuron Share News (RENE)

Germ-killing product supplier Byotrol said it has seen a significant increase in orders and now expects results for the financial year to September 30 to be ahead of expectations.Shares in Meridian Petroleum gushed higher after the oil and gas firm announced an increase in prospective resources in its Australian operations.Stem cell developer ReNeuron has received regulatory approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for clinical trial protocol amendments for the first-in-man clinical trial with ReN001, ReNeuron's stem cell therapy for stroke.The company added that its current cash resources are expected to last well into the second quarter of next year. 'The company will look to seek further equity-based funding at the appropriate time and is also actively pursuing a number of non-dilutive governmental, regional and charitable translational funding sources, such as the UK Technology Strategy Board's recently announced programme to fund commercial research and development projects in regenerative medicine,' the company added.Bid target Accuma saw its loss before tax from continuing operations balloon to £1.74m in the first half of 2009 from a loss of £0.05m a year earlier, after it made a £1.5m provision for impairment losses. The debt consultant's revenue fell to £1.44m from £1.74m. Revenues rose sharply and losses reduced substantially in the year to end-June at flat panel loudspeaker company NXT. Revenue jumped to £3.36m from £2.08m the year before while loss before tax narrowed to £0.70m from £2.23m.A one-off licensing revenue payment from Sciele group helped drug Plethora post revenues of £15.8m and a profit after tax of £10.8m in the half year to June. Revenues for the second half of the year will be significantly lower than the first six months of the year, though operating costs have been reduced substantially and the benefit of this will be seen in the second half of the year.IT solutions groups K3 has raised £1.5m through a placing at 85p, a 2.9% discount to the closing mid market price on 16 September 2009.Online ad agency Infoserve's performance over the last three months has shown further continued improvement, with cash generated from trading averaging £26k per month, it told shareholders at the AGM. Once again, the impact of the IAS18 revenue adjustment means that cash generation exceeds reported EBITDA by some £38k per month.As group revenues grow, so the available renewal revenues increase. The group also expects the current trend of growing new business sales to be maintained and, therefore, revenues to continue to improve. During July and August, the traditionally quiet holiday season, average sales per day reached new historic highs, it said.